| 1 |
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
| 2 |
Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and HopesLung Cancer Immunotherapy: Facts and Hopes[J]. Clin Cancer Res, 2019, 25(15): 4592-4602.
|
| 3 |
Mamdani H, Matosevic S, Khalid AB, et al. Immunotherapy in Lung Cancer: Current Landscape and Future Directions[J]. Front Immunol, 2022, 13: 823618.
|
| 4 |
Wang L, Zhao D, Qin K, et al. Effect and biomarker of Nivolumab for non-small-cell lung cancer[J]. Biomed Pharmacother, 2019, 117: 109199.
|
| 5 |
Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆[J]. Ann Oncol, 2021, 32(5): 631-641.
|
| 6 |
Franzin R, Netti GS, Spadaccino F, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand？[J]. Front Immunol, 2020, 11: 574271-574291.
|
| 7 |
Riano I, Abuali I, Sharma A, et al. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer[J]. Pharmaceuticals (Basel), 2023, 16(2): 233-245.
|
| 8 |
鲁德玕，鲁嘉萌，姬晓青，等. IL-27与T细胞免疫[J]. 国际免疫学杂志，2019, 42(6): 655-661.
|
| 9 |
Carbotti G, Nikpoor AR, Vacca P, et al. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 1-12.
|
| 10 |
Petretto A, Carbotti G, Inglese E, et al. Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells[J]. Oncotarget, 2016, 7(45): 72518-72537.
|
| 11 |
Airoldi I, Tupone M G, Esposito S, et al. Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer[J]. Oncotarget, 2015, 6(6): 3694-3708.
|
| 12 |
Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer[J]. Cancer Med, 2018, 7(1): 13-20.
|
| 13 |
Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(3): 351-357.
|
| 14 |
Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer[J]. Cancer Med, 2018, 7(1): 13-20.
|
| 15 |
刘 磊，李福霞，禚孝丽，等. 免疫检查点抑制剂疗效预测生物标志物在非小细胞肺癌中的研究进展[J]. 中华肿瘤防治杂志，2022, 29(22): 1628-1635.
|
| 16 |
Del Re M, Cucchiara F, Rofi E, et al. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC[J]. Cancer Immunol Immunother, 2021, 70(6): 1667-1678.
|
| 17 |
Liu Y, Zugazagoitia J, Ahmed FS, et al. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy[J]. Clin Cancer Res, 2020, 26(4): 970-977.
|
| 18 |
Niu M, Yi M, Li N, et al. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC[J]. Exp Hematol Oncol, 2021, 10(1): 1-13.
|
| 19 |
Oitabén A, Fonseca P, Villanueva MJ, et al. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC[J]. Cancers (Basel), 2022, 14(11): 2626-2647.
|
| 20 |
Hao L, Hu Y, Hu J, et al. Case report: A squamous cell lung carcinoma patient who responded to neoadjuvant immunochemotherapy but died from anastomosis leakage or/and irAEs: Immune microenvironment and genomic features changes[J]. Front Oncol, 2021, 11: 674328.
|
| 21 |
Kim DH, Kim HR, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer[J]. Exp Mol Med, 2019, 51(8): 1-13.
|
| 22 |
Niu M, Liu Y, Yi M, et al. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer[J]. Front Immunol, 2022, 13: 827921.
|
| 23 |
Sadagopan A, Michelakos T, Boyiadzis G, et al. Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the Era of checkpoint inhibitors: A review[J]. JAMA Oncol, 2022, 8(3): 462-473.
|
| 24 |
Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology and immunotherapy[J]. Mediators Inflamm, 2017: 1-14.
|
| 25 |
Wang Q, Liu J. Regulation and immune function of IL-27[J]. Adv Exp Med Biol, 2016, 941: 191-211.
|
| 26 |
Carbotti G, Barisione G, Airoldi I, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells[J]. Oncotarget, 2015, 6(41): 43267-43280.
|
| 27 |
Zhao S, Ren S, Jiang T, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer apatinib potentiates anti-PD-1/PD-L1 effect in lung cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643.
|
| 28 |
Gao Y, Yang J, Cai Y, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling[J]. Int J Cancer, 2018, 143(4): 931-943.
|
| 29 |
Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964.
|
| 30 |
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy：harnessing potential synergies[J]. Cancer Immunol Res, 2015, 3(5): 436-443.
|